Sequent Scientific Limited (SEQUENT.BO)
INR 136.85
(3.52%)
INR 136.85
(3.52%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 13.69 Billion INR | -3.42% |
| 2022 | 14.18 Billion INR | 0.57% |
| 2021 | 14.1 Billion INR | 4.3% |
| 2020 | 13.52 Billion INR | 16.5% |
| 2019 | 11.6 Billion INR | 13.59% |
| 2018 | 10.21 Billion INR | 21.34% |
| 2017 | 8.41 Billion INR | 24.11% |
| 2016 | 6.78 Billion INR | 12.8% |
| 2015 | 6.01 Billion INR | 36.48% |
| 2014 | 4.4 Billion INR | 11.97% |
| 2013 | 3.93 Billion INR | 20.69% |
| 2012 | 3.26 Billion INR | -5.4% |
| 2011 | 3.44 Billion INR | 10.52% |
| 2010 | 3.11 Billion INR | 9.65% |
| 2009 | 2.84 Billion INR | 97.5% |
| 2008 | 1.44 Billion INR | 92.55% |
| 2007 | 747.96 Million INR | 67.25% |
| 2006 | 447.21 Million INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 3.9 Billion INR | 8.03% |
| 2023 FY | 13.69 Billion INR | -3.42% |
| 2023 Q1 | 3.33 Billion INR | -8.47% |
| 2023 Q2 | 3.45 Billion INR | 3.83% |
| 2023 Q3 | 3.29 Billion INR | -4.8% |
| 2023 Q4 | 3.61 Billion INR | 9.67% |
| 2022 Q2 | 3.37 Billion INR | -1.09% |
| 2022 Q3 | 3.75 Billion INR | 11.17% |
| 2022 FY | 14.18 Billion INR | 0.57% |
| 2022 Q4 | 3.64 Billion INR | -3.01% |
| 2022 Q1 | 3.41 Billion INR | -10.43% |
| 2021 Q4 | 3.81 Billion INR | 6.43% |
| 2021 Q2 | 3.5 Billion INR | 9.37% |
| 2021 FY | 14.1 Billion INR | 4.3% |
| 2021 Q3 | 3.58 Billion INR | 2.14% |
| 2021 Q1 | 3.2 Billion INR | -4.97% |
| 2020 FY | 13.52 Billion INR | 16.5% |
| 2020 Q4 | 3.37 Billion INR | -5.01% |
| 2020 Q3 | 3.55 Billion INR | 1.6% |
| 2020 Q2 | 3.49 Billion INR | 18.36% |
| 2020 Q1 | 2.95 Billion INR | 4.76% |
| 2019 Q3 | 3.16 Billion INR | 11.33% |
| 2019 Q2 | 2.84 Billion INR | 2.23% |
| 2019 Q1 | 2.78 Billion INR | 5.66% |
| 2019 Q4 | 2.81 Billion INR | -10.93% |
| 2019 FY | 11.6 Billion INR | 13.59% |
| 2018 Q1 | 2.35 Billion INR | 11.38% |
| 2018 Q4 | 2.63 Billion INR | -2.74% |
| 2018 Q3 | 2.7 Billion INR | 7.47% |
| 2018 Q2 | 2.51 Billion INR | 7.05% |
| 2018 FY | 10.21 Billion INR | 21.34% |
| 2017 Q2 | 1.97 Billion INR | 2.55% |
| 2017 FY | 8.41 Billion INR | 24.11% |
| 2017 Q1 | 1.92 Billion INR | -52.98% |
| 2017 Q3 | 2.24 Billion INR | 13.86% |
| 2017 Q4 | 2.11 Billion INR | -6.13% |
| 2016 Q4 | 4.09 Billion INR | 97.23% |
| 2016 Q2 | 2.26 Billion INR | 37.35% |
| 2016 FY | 6.78 Billion INR | 12.8% |
| 2016 Q1 | 1.64 Billion INR | -6.17% |
| 2016 Q3 | 2.07 Billion INR | -8.24% |
| 2015 Q1 | 1.46 Billion INR | 35.04% |
| 2015 FY | 6.01 Billion INR | 36.48% |
| 2015 Q4 | 1.75 Billion INR | 17.23% |
| 2015 Q3 | 1.49 Billion INR | -4.52% |
| 2015 Q2 | 1.56 Billion INR | 7.4% |
| 2014 FY | 4.4 Billion INR | 11.97% |
| 2014 Q4 | 1.08 Billion INR | -2.72% |
| 2014 Q3 | 1.11 Billion INR | 5.44% |
| 2014 Q2 | 1.05 Billion INR | -5.31% |
| 2014 Q1 | 1.11 Billion INR | 6.06% |
| 2013 Q3 | 1.15 Billion INR | 1.25% |
| 2013 Q1 | 1.17 Billion INR | 7.94% |
| 2013 Q4 | 1.05 Billion INR | -9.01% |
| 2013 FY | 3.93 Billion INR | 20.69% |
| 2013 Q2 | 1.14 Billion INR | -2.87% |
| 2012 Q2 | 629.58 Million INR | -12.15% |
| 2012 FY | 3.26 Billion INR | -5.4% |
| 2012 Q1 | 716.62 Million INR | 0.0% |
| 2012 Q3 | 826.92 Million INR | 31.34% |
| 2012 Q4 | 1.08 Billion INR | 31.54% |
| 2011 FY | 3.44 Billion INR | 10.52% |
| 2010 FY | 3.11 Billion INR | 9.65% |
| 2009 FY | 2.84 Billion INR | 97.5% |
| 2008 FY | 1.44 Billion INR | 92.55% |
| 2007 FY | 747.96 Million INR | 67.25% |
| 2006 FY | 447.21 Million INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 97.176% |
| NATCO Pharma Limited | 40.02 Billion INR | 65.774% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | -30.283% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | -428.356% |
| Achyut Healthcare Limited | 61.36 Million INR | -22219.591% |
| Ajanta Pharma Limited | 42.08 Billion INR | 67.455% |
| Alkem Laboratories Limited | 126.67 Billion INR | 89.187% |
| Alpa Laboratories Limited | 1.08 Billion INR | -1159.65% |
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | 77.59% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | -5.727% |
| Aurobindo Pharma Limited | 287.04 Billion INR | 95.228% |
| Bajaj HealthCare Limited | 4.73 Billion INR | -189.328% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | -77.831% |
| Brooks Laboratories Limited | 794.86 Million INR | -1623.233% |
| Divi's Laboratories Limited | 78.45 Billion INR | 82.54% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 95.093% |
| Eris Lifesciences Limited | 20.09 Billion INR | 31.825% |
| FDC Limited | 19.42 Billion INR | 29.502% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 88.405% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | 40.009% |
| Granules India Limited | 45.06 Billion INR | 69.605% |
| Gufic Biosciences Limited | 8.06 Billion INR | -69.802% |
| Hester Biosciences Limited | 3.04 Billion INR | -349.762% |
| Indoco Remedies Limited | 17.89 Billion INR | 23.455% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | -6.935% |
| Ipca Laboratories Limited | 76.22 Billion INR | 82.03% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | -556.309% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | -2616.561% |
| Lasa Supergenerics Limited | 1.04 Billion INR | -1212.82% |
| Laurus Labs Limited | 50.01 Billion INR | 72.615% |
| Lupin Limited | 200.1 Billion INR | 93.155% |
| Mankind Pharma Limited | 103.34 Billion INR | 86.746% |
| Medicamen Biotech Limited | 1.79 Billion INR | -663.906% |
| Medico Remedies Limited | 1.44 Billion INR | -845.159% |
| Megasoft Limited | 373.95 Million INR | -3562.843% |
| Piramal Pharma Limited | 81.71 Billion INR | 83.237% |
| RPG Life Sciences Limited | 5.82 Billion INR | -135.329% |
| Sigachi Industries Limited | 3.98 Billion INR | -243.329% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | -1713.125% |
| Unichem Laboratories Limited | 16.57 Billion INR | 17.357% |
| Wanbury Limited | 5.75 Billion INR | -137.945% |
| Windlas Biotech Limited | 6.3 Billion INR | -117.088% |
| ZIM Laboratories Limited | 3.67 Billion INR | -272.793% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 92.799% |
| Procter & Gamble Health Limited | 11.51 Billion INR | -18.977% |
| Amrutanjan Health Care Limited | 4.21 Billion INR | -225.174% |
| Bal Pharma Limited | 3.39 Billion INR | -303.789% |
| Strides Pharma Science Limited | 40.51 Billion INR | 66.189% |
| Venus Remedies Limited | 5.91 Billion INR | -131.589% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | 24.554% |
| Nectar Lifesciences Limited | 16.84 Billion INR | 18.666% |
| Shilpa Medicare Limited | 11.51 Billion INR | -18.941% |
| Aarti Drugs Limited | 25.28 Billion INR | 45.83% |
| IOL Chemicals and Pharmaceuticals Limited | 21.18 Billion INR | 35.358% |
| Suven Life Sciences Limited | 116.92 Million INR | -11614.211% |
| Ind-Swift Limited | 5.02 Billion INR | -172.601% |
| Valiant Laboratories Limited | 1.82 Billion INR | -652.363% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.84 Billion INR | 60.687% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | -10.606% |
| Themis Medicare Limited | 3.81 Billion INR | -258.793% |
| Hikal Limited | 17.84 Billion INR | 23.247% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 87.085% |
| Novartis India Limited | 3.35 Billion INR | -308.79% |
| Wockhardt Limited | 27.89 Billion INR | 50.888% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 79.565% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -3321.308% |
| Neuland Laboratories Limited | 15.58 Billion INR | 12.117% |
| Morepen Laboratories Limited | 17.01 Billion INR | 19.518% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | -787.29% |
| Mangalam Drugs & Organics Limited | 3.68 Billion INR | -271.609% |